Nluc Reporter Cell Line - NCI-H929

NCI-H929 is a highly utilized human multiple myeloma cell line, originally established from a malignant pleural effusion of a 62-year-old female patient. Growing in suspension with characteristic plasmacytoid morphology, NCI-H929 is a cornerstone model for studying plasma cell dyscrasias. It is particularly noted for producing IgA kappa immunoglobulin, expressing classic multiple myeloma surface markers such as CD38, CD138 (syndecan-1), and BCMA, and harboring the high-risk t(4;14) chromosomal translocation. The Nluc Reporter Cell Line - NCI-H929 elevates this foundational hematological model through the stable genetic integration of the NanoLuc (Nluc) reporter gene. NanoLuc is a highly engineered, exceptionally compact (19.1 kDa) luciferase enzyme derived from the deep-sea shrimp Oplophorus gracilirostris. When catalyzed by its specific substrate, furimazine, it generates a sustained, high-intensity luminescent signal that is frequently up to 100 times brighter than conventional firefly luciferase. Most importantly, the engineered Nluc-NCI-H929 cells strictly retain the biological identity, suspension growth dynamics, and critical mutational and phenotypic profiles of the parental line, providing a biologically authentic and highly sensitive platform for advanced myeloma research.

The integration of the ultra-bright NanoLuc reporter transforms the NCI-H929 cell line into an exceptionally powerful tool for both in vitro analytics and complex preclinical animal modeling, particularly within the rapidly advancing fields of targeted immunotherapy. On the laboratory bench, the intense luminescent output enables highly sensitive detection of minute cell populations. This provides an ideal platform for high-throughput screening of novel anti-myeloma agents, such as next-generation proteasome inhibitors, and for evaluating the precise cytotoxicity of emerging immunotherapies—including BCMA-targeted CAR-T cells, natural killer (NK) cells, and bispecific T-cell engagers (BiTEs). In preclinical animal studies, this reporter line serves as an optimal standard for establishing systemic, disseminated models of human multiple myeloma. Following intravenous injection into highly immunodeficient mice, the Nluc-NCI-H929 cells naturally home to and engraft within the bone marrow niche, closely mimicking clinical disease progression.